NCT01353482 arm group ffb145fe0cc84de62f18df06a5509394 [clinicaltrials_resource:NCT01353482/arm-group/ffb145fe0cc84de62f18df06a5509394]
Cisplatin [clinicaltrials_resource:c7e4d2aff2e2f432a9e73d440de28d4a]Placebo [clinicaltrials_resource:d8c54368bbc6baa725f9a58b1d71d9f8]Pemetrexed [clinicaltrials_resource:deef731a1e734c3ae7e97316c5426f41]A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma [clinicaltrials:NCT01353482]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01353482 arm group ffb145fe0cc84de62f18df06a5509394 [clinicaltrials_resource:NCT01353482/arm-group/ffb145fe0cc84de62f18df06a5509394]
Bio2RDF identifier
NCT01353482/arm-group/ffb145fe0cc84de62f18df06a5509394
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... b145fe0cc84de62f18df06a5509394
description [clinicaltrials_vocabulary:description]
If the patient is randomised i ...... days as in the vorinostat arm.
identifier
clinicaltrials_resource:NCT01353482/arm-group/ffb145fe0cc84de62f18df06a5509394
title
NCT01353482 arm group ffb145fe0cc84de62f18df06a5509394
@en
type
label
NCT01353482 arm group ffb145fe ...... 145fe0cc84de62f18df06a5509394]
@en